AIMDW NASDAQ

Ainos, Inc. operates as a healthcare enterprise dedicated to advancing medical technologies. Its core focus involves developing both point-of-care diagnostic solutions and innovative, safe therapeutic options for various health conditions. The company's offerings include a COVID-19 antigen rapid test kit. This is complemented by the Ainos' cloud-based test management App, a holistic platform comprising the rapid test kit, a personal mobile application, and an enterprise-level app. Ainos also provides a COVID-19 nucleic acid test. Further technologies under development or offered include point-of-care testing for volatile organic compounds and Very Low-Dose Oral Interferon Alpha, an oral formulation of IFN-a with broad therapeutic potential. The firm is additionally developing a Synthetic RNA (SRNA) technology platform, with specific work being conducted in Taiwan. Beyond these, Ainos' product line extends to women's health, pneumonia, the Ainos Pen, AI Nose, and a variety of other products. Originally incorporated in 1984, the company was formerly known as Amarillo Biosciences, Inc. and rebranded to Ainos, Inc. in May 2021. Its main operations are based in San Diego, California.